Platelet α2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol

Journal of Hypertension

Volumn 18, Issue 2, 2000, Pages 217-221

  Portaluppi, Francesco ^a   Manfredini, Roberto ^a   Varani, Katia ^a   Gessi, Stefania ^a   Caiazza, Alberto ^b   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Fidenza Hospital   (Italy)

Author keywords

Binding assays; Doxazosin; Essential hypertension; Human platelets; Propranolol; adrenergic blocker; adrenergic blocker

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DOXAZOSIN; PROPRANOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; THROMBOCYTE; BLOOD; CASE CONTROL STUDY; CELL MEMBRANE; DRUG EFFECT; HYPERTENSION; IN VITRO STUDY; KINETICS; METABOLISM; MIDDLE AGED;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL MEMBRANE; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; KINETICS; MALE; MIDDLE AGED; PROPRANOLOL; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0033621974     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018020-00013     Document Type: Article

References (29)

1. 1 Gavras H, Handy D, Gavras I. Alpha-adrenergic receptors in hypertension. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press; 1995. pp. 853-861.
2. 2 Michel MC, Bradde OE, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990; 16:107-120.
3. 3 Blankesteijn WM, Graafsma SJ, van Tits LI, Hectors MP, Thien T. Adrenoceptors on blood cells in patients with primary hypertension: correlation with blood pressure and related variables. J Hypertens 1993; 11:995-1002.
4. 4 MacKinnon AC, Spedding M, Brown CM. Sodium modulation cf 3H-agonist and 3H-antagonist binding to alpha 2-adrenoceptor subtypes. Br J Pharmacol 1993; 109:371-378.
5. 5 Taylor P, Insel PA. Molecular basis of pharmacologie selectivity In: Pratt WB, Taylor P (editors): Principles of drug action - the basis of pharmacology. New York: Churchill Livingstone; 1990. pp. 1-102.
6. 6 Varani K, Gessi S, Caiazza A. Rastelli G, Portaluppi F, Borea PA. Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br J Clin Pharmacol 1999; 47:167-172.
7. 7 Schloos J, Wellstein A, Palm D. Agonist binding at alpha 2-adrenoceptors of human platelets using 3H-UK 14304: regulation by Gpp(NH)p and cations. Naunyn Schmiedebergs Arch Pharmacol 1987; 336:48-59.
8. 8 Neutel JM, Taylor SH, Smith DHG, Weber MA, Aepfelbacher FC. doxazosin. In: Messerli FH (editor): Cardiovascular drug therapy. Philadelphia, PA: WB Saunders; 1996. pp. 681-689.
9. 9 Wessels F. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension. Am Heart J 1991; 121:299-303.
10. 10 Carruthers G, Dessain P, Fodor G, Newman C, Palmer W, Sim D. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. Am J Cardiol 1993; 71:575-581.
11. 11 The sixth report of the Joint National Committee on prevention, detection. evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
12. 12 Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263:407-413.
13. 13 Prichard BN, Owens CW. Mode of action of beta-adrenergic blocking drugs in hypertension. Clin Physiol Biochem 1990; 8:1-10.
14. 14 Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol 1990; 66:66G-70G.
15. 15 Olsson G, Ryden L. Prevention of sudden death using beta-blockers. Review of possible contributory actions. Circulation 1991; 84:VI33-VI37.
16. 16 Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
17. 17 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
18. 18 Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107:220-239.
19. 19 Amann FW, Bolli P, Kiowski W, Buhler FR. Enhanced alpha-adrenoreceptor-mediated vasoconstriction in essential hypertension. Hypertension 1981; 3:I119-I123.
20. 20 Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1980; 32:337-362.
21. 21 Timmermans PB, van Zwieten PA. Mini-review. The postsynaptic alpha 2-adrenoreceptor. J Auton Pharmacol 1981; 1:171-183.
22. 22 Bolli P, Erne P, Ji BH, Block LH, Kiowski W, Buhler FR. Adrenaline induces vasoconstriction through post-junctional alpha 2 adrenoceptors and this response is enhanced in patients with essential hypertension. J Hypertens 1984; 2:S115-S118.
23. 23 Kenakin T. Stimulus-response mechanisms. In: Kenakin T (editor): Pharmacologic analysis of drug-receptor interaction. New York: Raven Press; 1993. pp. 39-68.
24. 24 Hansson L. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand 1973; 194:1-40.
25. 25 Chichester CO, Rodgers RL. Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1987; 10:S21-S26.
26. 26 Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 1991; 40:321-326.
27. 27 Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991; 121:251-260.
28. 28 Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. Am Heart J 1991; 121:1307-1311.
29. 29 Young RA, Brogden RN. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 1988; 35:525-541.